FDA Announces Public Meeting of Cardiovascular and Renal Drugs Advisory Committee to Discuss New Drug Application for FABHALTA (iptacopan) Oral Capsules

Summary

The US Food and Drug Administration (FDA) is hosting a public meeting of the Cardiovascular and Renal Drugs Advisory Committee to discuss a new drug application for FABHALTA (iptacopan) Oral Capsules, and is seeking public comments on the proposal.